DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma
The First Affiliated Hospital of Xiamen University
60 participants
Dec 1, 2025
INTERVENTIONAL
Conditions
Summary
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
Eligibility
Inclusion Criteria5
- Adult patients (aged 18 years or older);
- Patients with suspected, newly diagnosed, and previously treated neuroendocrine carcinoma(supporting evidence may include imaging findings and pathology report);
- Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
- Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;
Exclusion Criteria2
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
- Inability to complete PET/CT imaging.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will undergo DLL3-Targeted PET/CT imaging for the evaluation of tumor lesions. Imaging findings will be compared with conventional imaging modalities as part of the study analysis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07458906